Page 12 - Delaware Medical Journal - October 2016
P. 12
CANCER CLINICAL TRIAL
NCI PROTOCOL OF THE MONTH
GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Onnly Recurrence of Carcinoma of the Uterine Corpus
Objectives:
Pimary Objective:
To assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina.
Secondary Objectives:
1. To capture the sites of recurrence subsequent to treatment with pelvic radiation with or without concurrent weekly cisplatin in women with recurrent uterine carcinoma.
2. To estimate overall survival of patients with recurrent uterine carcinoma treated with pelvic radiation therapy with or without concurrent weekly cisplatin.
3. presence of lymph-vascular space involvement of the original tumor at the time of initial hysterectomy
4. To evaluate toxicity derived from the combined cisplatin and radiation compared with radiation alone in this patient population.
Eligibilty:
extrapelvic disease.
Must have undergone complete hysterectomy and bilateral salpingo-oophorectomy at the time of the original therapy for their
uterine carcinoma.
Primary surgical debulking before protocol therapy is permissible. This would include removal of gross symptomatic disease in
the present recurrence are not eligible.
Performance status 0-2.
Adequate organ function.
Treatment:
random treatment allocation to one of the following treatment arms:
by vaginal brachytherapy**
versus
completion of external beam irradiation.
The Delaware Cancer Treatment Program (DCTP) provides medical insurance coverage to uninsured Delawareans for the treatment of cancer. Call 302-744-1040 for more information.
For information regarding clinical trials
or if you would like to have the list of open protocols e-mailed to you, akee@christianacare.org.
300 Del Med J | October 2016 | Vol. 88 |
No. 10
